Pharmaceuticals APAC

APAC AI in Drug Repurposing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC AI in Drug Repurposing Market Industry Trends and Forecast to 2034: Segmented by (Approach, Indication, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $114.8 Mn Placeholder estimate
Estimate 2025 $141.5 Mn 23.8% of the global market
Projected 2034 $932.3 Mn 558.7% Adds $790.7 Mn over 9 forecast years
CAGR 2025–2034 23.3% Faster than 90% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 23.77% of the global market.
  • Among regions, the largest is North America at $266.8 Mn.
  • Fastest growing: Africa at 23.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$790.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
AI in Drug Repurposing Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $114.8 Mn — —
2025 (base) $141.5 Mn +$26.7 Mn —
2026 (forecast) $174.5 Mn +$33.0 Mn +23.3%
2027 (forecast) $215.2 Mn +$40.7 Mn +52%
2028 (forecast) $265.3 Mn +$50.1 Mn +87.5%
2029 (forecast) $327.1 Mn +$61.8 Mn +131.1%
2030 (forecast) $403.4 Mn +$76.2 Mn +185%
2031 (forecast) $497.3 Mn +$94.0 Mn +251.4%
2032 (forecast) $613.2 Mn +$115.9 Mn +333.3%
2033 (forecast) $756.1 Mn +$142.9 Mn +434.2%
2034 (forecast) $932.3 Mn +$176.2 Mn +558.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC AI in Drug Repurposing Market Analysis at a glance
Market size, 2025$141.5 Mn placeholder estimate
Forecast, 2034$932.3 Mn placeholder estimate
Growth (CAGR), 2025–203423.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledArtificial Intelligence in Drug Repurposing
SegmentsApproach and indication (see all)
Key playersBenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals, Every Cure (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC AI in Drug Repurposing Market Analysis Executive Summary

AI in drug repurposing searches data to find new uses for existing medicines, cutting the time and cost of development.

Key segments of the AI in Drug Repurposing market include approach (Knowledge Graphs, Machine Learning on Omics and Real-World Data Mining) and indication (Rare Diseases, Oncology and Infectious Diseases).

Bar chart: Asia Pacific AI in Drug Repurposing market size, 2024–2034, placeholder estimates. $114.8 Mn in 2024, $141.5 Mn in 2025 and $932.3 Mn in 2034, 23.3% CAGR.
Asia Pacific AI in Drug Repurposing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC AI in Drug Repurposing Market Dynamics

Market Growth Drivers

Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.

Opportunity

Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Drug Repurposing market strong growth, including in emerging health systems.

Market Restraints

Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Drug Repurposing market.

Competitive Landscape for AI in Drug Repurposing Market in APAC

The AI in Drug Repurposing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for AI in Drug Repurposing Market in APAC

AI in Drug Repurposing in APAC: rules and payment

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9] and Thai FDA (Thailand)⁠[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[11], basic medical insurance (China)⁠[12], the Hospital Authority (Hong Kong)⁠[13], Ayushman Bharat PM-JAY (India)⁠[14], public health insurance (Japan)⁠[15], subsidised public care (Malaysia)⁠[16], Pharmac (New Zealand)⁠[17], PhilHealth (Philippines)⁠[18], MediShield Life (Singapore)⁠[19] and the Universal Coverage Scheme (Thailand)⁠[20].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[12] National Healthcare Security Administration. Checked 14 Nov 2026.

[13] Hospital Authority. Checked 14 Nov 2026.

[14] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[15] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[16] Ministry of Health Malaysia. Checked 14 Nov 2026.

[17] Pharmac. Checked 14 Nov 2026.

[18] PhilHealth. Checked 14 Nov 2026.

[19] CPF Board, MediShield Life. Checked 14 Nov 2026.

[20] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AI in Drug Repurposing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in AI in Drug Repurposing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

AI in Drug Repurposing in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the AI in Drug Repurposing market in Asia Pacific?
Placeholder estimate: about $141.5 Mn in 2025, rising to about $932.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the AI in Drug Repurposing market in Asia Pacific growing?
Placeholder estimate: about 23.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the AI in Drug Repurposing market report cover?
The report splits the market by approach (Knowledge Graphs, Machine Learning on Omics, Real-World Data Mining) and indication (Rare Diseases, Oncology, Infectious Diseases, Neurology).
Who are the key players in the AI in Drug Repurposing market?
Key players include BenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals and Every Cure.
What is driving the AI in Drug Repurposing market?
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.
How much research is published on AI in Drug Repurposing?
PubMed lists 1,006 papers on AI in Drug Repurposing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on artificial intelligence and drug development and manufacturing

See the topic